LB Pharmaceuticals Inc LBRX
40.85 USD +0.52 (+1.29%)
At closeNov 4, 2026, 4:00 PM EST
40.85 0.00 0.00%
After hours · Nov 4, 4:00 PM ET
38.75 Day range 41.40
14.32 52-week range 50.16
- YTD
- +83.51%
- 1 year
- +147.58%
Financial health
Altman Z-Score
26.12 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 3
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 3
Valuation
P/E -22.3×
FY 2022 5y median -7.0× FY 2025
P/S 0.0×
FY 2022 5y median 0.0× FY 2025
P/B 1.9×
FY 2022 5y median -1.2× FY 2025
P/FCF -16.0×
FY 2022 5y median -10.5× FY 2025
EV/EBITDA -12.7×
FY 2022 5y median -9.0× FY 2025
EV/Sales 0.0×
FY 2022 5y median 0.0× FY 2025
FCF Yield -6.3%
FY 2022 5y median -13.0% FY 2025
Profitability
Gross Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2022 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2022 5y median 0.0% FY 2025
ROE -8.4%
FY 2022 5y median 34.0% FY 2025
ROIC -9.9%
FY 2022 5y median -19.9% FY 2025
ROA -8.1%
FY 2022 5y median -40.3% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2022 FY 2025
Operating Income 53.1%
FY 2022 FY 2025
EPS (diluted) 94.4%
FY 2022 FY 2025
Free Cash Flow 34.5%
FY 2022 FY 2025
Financial Health
Current Ratio 41.4×
FY 2022 5y median 29.5× FY 2025
Quick Ratio 41.4×
FY 2022 5y median 29.5× FY 2025
Debt / Equity 0.0×
FY 2022 5y median -0.0× FY 2025
Net Debt / EBITDA 9.9×
FY 2022 5y median 5.1× FY 2025
Interest Coverage 0.0×
FY 2022 5y median -0.7× FY 2025
Dividends
Dividend Yield 0.0%
FY 2022 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2022 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31